London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Tracking this for last few days....looks very strong
There are now 101m shares in circulation. Market cap £23m (using rounded numbers) so while it is easy:
50p = £50m
£1 = £100m
£3 = £300m
£5 = £500m
£10 = £1bn
The value of Sareums pipeline is still to be determined and is dependent on positive newsflow. Brighty has posted several valuations of done deals for reference.
It is for each of us as individuals to assess the potential value of Sareum and those happy with £1 is fine. £3 & £5 per share are good with £10 per share life changing for many.
Sareums pipeline is currently valued at £23m for the lot if you believe the market. Risk v Reward looks excellent but it remains your choice.
@Funnyguy, Surfie,Joey etc- not a prediction but even you guys might be able to recognise value when it is staring you in the face.
Don't forget it's Thursday, Sar do like a Thursday.
Finally
Post at 9.17am...'shouldn't have a problem buying'...
I and many others can assure you that it is extremely difficult buying amounts this morning!!
SAR is hugely in demand, with ONLY 98.5M shares !
It's been a while but I have redeveloped the 'itch' in my left spherical like when we went from 1p to 9p old money..........
a sign from above?
Gonna wait for some sells to appear and tryagain 😁
Another great day of rises
The added bonus is that AIM company is using their A.I technology to help Sareum lead assets . There is avery good chance SAR trials will be positive as the success rate of PYC tech is very high and work with Merck, Sar etc
Snap
If you think it's rising superfast boyasaka, just take a look at the 3-month graph above. Nice gentle upswing currently, nothing like the dramatic drops that got us down here. Plenty of scope for more, with inevitable (and perfectly healthy) profit-taking along the way.
Just tried £50k, £25k, £10K AND £5K but no shares available to buy through Halifax............
Those that have been shareholders in Sareum for many moons will know that:
1. In combination with Dexamethasone the SAR science works.
2. In combination with AstraZeneca's WEE1 inhibitor Adavosertib the SAR science works.
3. In combination with Merck’s Keytruda the SAR science works.
4. In combination with Eli Lillys Gemcitabine the SAR science works
and we know
5.SDC-1801 reduced the levels of cytokines associated with Acute Respiratory Distress Syndrome (ARDS) in human lung cells infected with SARS-CoV-2 and demonstrated a profile that was superior to the anti-inflammatory steroid dexamethasone and similar to the JAK1/JAK2 inhibitor baricitinib.
i.e.IMO it is a no-brainer that very soon a major pharmaceutical company is going to do a licencing deal with Sareum based on the above information. Finance might not be the BOD's forte but science certainly is.
NT on ii for buys.
Up 13.41%. Nice.
Nice £18k buy. Looks like that run of sells was accounted for.
Way over done and just a start.
My purchase of £1950 shows as a sell as do a number of purchases at the sametime , looks likeMM are short of stock
D:
"Up another 23% today to 23p"
Bit early to be on the sauce old boy....
Up another 23% today to 23p
Been climbing back since 3rd April when it fell back to 10.25p just above placing price of 10p
Nearly back to the pre Hardman & Co report I posted on 11th February below.
The AIM Casino.
Newbies getting euphoric - I need a 1 in front of the current price before I start feeling better!!
With no TR1 this morning. All we really know is they have less 3% of shares in issue. I think we will get an RNS late this afternoon stating we are giving them another 3 million. Not a problem if demand is still high. It would be nice if we could get and accurate balance of amount owed in the RNS. Hopefully we are well under £500k now.
Interesting link below. One of the Indications in SDC1801 patent description is Alzheimers
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.12445#:~:text=The%20use%20of%20baricitinib%20in,CNS%20and%20may%20suppress%20neuroinflammation.
Regards
Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent
https://advancesinrheumatology.biomedcentral.com/articles/10.1186/s42358-024-00368-w
TYK2 inhibition with deucravacitinib ameliorates erosive oral lichen planushttps://onlinelibrary.wiley.com/doi/full/10.1111/exd.15080
https://biotech-insider.com/how-takeda-beat-almost-every-biopharmaceutical-company-to-win-nimbus-tyk2-med/
Shouldn't have a problem buying.
Riverfort can forward sell. They don't have many left l might add.
Sp will still rise steadily as market cap still low.
Regards
The takeaway for me has to be that there were 15 Phase I deals signed in 2023, double compared to 2022. Very encouraging to read that. With patents expiring soon at many of the major pharmaceutical companies they will be looking to on-licence new candidates. That has to be good news for SDC-1801 and therefore Sareum's shareholders. Topline data is out soon. It could be a game changing few weeks here.